Effects of Lumacaftor/Ivacaftor in a Pediatric Cohort Homozygous for F508del-CFTR

被引：1
|
作者：
Egan, Marie E. [1 ,2 ]
机构：
[1] Yale Sch Med, Dept Pediat, New Haven, CT 06520 USA
[2] Yale Sch Med, Dept Cellular & Mol Physiol, New Haven, CT 06520 USA
来源：
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE | 2017年 / 195卷 / 07期
关键词：
CYSTIC-FIBROSIS; PHE508DEL CFTR; IVACAFTOR; MUTATION; TRIAL;
D O I：
10.1164/rccm.201611-2290ED
中图分类号：
R4 [临床医学];
学科分类号：
1002 ; 100602 ;
摘要：
引用
收藏
页码：849 / 850
页数：2
相关论文
共 50 条
  • [1] Lumacaftor/ivacaftor in patients with cystic fibrosis and advanced lung disease homozygous for F508del-CFTR
    Taylor-Cousar, Jennifer L.
    Jain, Manu
    Barto, Tara Lynn
    Haddad, Tarik
    Atkinson, Jeffrey
    Tian, Simon
    Tang, Rui
    Marigowda, Gautham
    Waltz, David
    Pilewski, Joseph
    JOURNAL OF CYSTIC FIBROSIS, 2018, 17 (02) : 228 - 235
  • [2] SAFETY AND EFFICACY OF TREATMENT WITH LUMACAFTOR IN COMBINATION WITH IVACAFTOR IN PATIENTS WITH CF HOMOZYGOUS FOR F508DEL-CFTR
    Konstan, M. W.
    Ramsey, B. W.
    Elborn, J.
    Boyle, M. P.
    Waltz, D.
    Marigowda, G.
    Nair, N.
    Wainwright, C. E.
    PEDIATRIC PULMONOLOGY, 2015, 50 : 269 - 270
  • [3] Efficacy of lumacaftor-ivacaftor for the treatment of cystic fibrosis patients homozygous for the F508del-CFTR mutation
    Cholon, Deborah M.
    Esther, Charles R., Jr.
    Gentzsch, Martina
    EXPERT REVIEW OF PRECISION MEDICINE AND DRUG DEVELOPMENT, 2016, 1 (03): : 235 - 243
  • [4] Clinical Effectiveness of Lumacaftor/Ivacaftor in Patients with Cystic Fibrosis Homozygous for F508del-CFTR A Clinical Trial
    Sagel, Scott D.
    Khan, Umer
    Heltshe, Sonya L.
    Clancy, John P.
    Borowitz, Drucy
    Gelfond, Daniel
    Donaldson, Scott H.
    Moran, Antoinette
    Ratjen, Felix
    VanDalfsen, Jill M.
    Rowe, Steven M.
    ANNALS OF THE AMERICAN THORACIC SOCIETY, 2021, 18 (01) : 75 - 83
  • [5] Lumacaftor/Ivacaftor Treatment of Patients with Cystic Fibrosis Heterozygous for F508del-CFTR
    Rowe, Steven M.
    McColley, Susanna A.
    Rietschel, Ernst
    Li, Xiaolei
    Bell, Scott C.
    Konstan, Michael W.
    Marigowda, Gautham
    Waltz, David
    Boyle, Michael P.
    ANNALS OF THE AMERICAN THORACIC SOCIETY, 2017, 14 (02) : 213 - 219
  • [6] COMBINATION LUMACAFTOR/IVACAFTOR THERAPY IMPROVES INFLAMMATORY BIOMARKERS IN PATIENTS WITH CF HOMOZYGOUS FOR THE F508DEL-CFTR MUTATION
    Sullivan, J. C.
    Accurso, F. J.
    Marigowda, G.
    Beusmans, J.
    Geho, D.
    Zhang, E.
    Moss, R.
    Waltz, D.
    PEDIATRIC PULMONOLOGY, 2016, 51 : 274 - 275
  • [7] EFFECT OF LUMACAFTOR IN COMBINATION WITH IVACAFTOR IN PATIENTS WITH CYSTIC FIBROSIS WHO ARE HOMOZYGOUS FOR F508DEL-CFTR: TRANSPORT STUDY
    Ramsey, B.
    Boyle, M. P.
    Elborn, J.
    Huang, X.
    Marigowda, G.
    Waltz, D.
    Wainwright, C. E.
    PEDIATRIC PULMONOLOGY, 2014, 49 : 305 - 305
  • [8] EFFECT OF LUMACAFTOR IN COMBINATION WITH IVACAFTOR IN PATIENTS WITH CYSTIC FIBROSIS WHO ARE HOMOZYGOUS FOR F508DEL-CFTR: THE TRAFFIC STUDY
    Elborn, J.
    Wainwright, C. E.
    Ramsey, B.
    Huang, X.
    Marigowda, G.
    Waltz, D.
    Boyle, M. P.
    PEDIATRIC PULMONOLOGY, 2014, 49 : 304 - 305
  • [9] Lumacaftor/Ivacaftor in Patients Aged 6-11 Years with Cystic Fibrosis and Homozygous for F508del-CFTR
    Milla, Carlos E.
    Ratjen, Felix
    Marigowda, Gautham
    Liu, Fang
    Waltz, David
    Rosenfeld, Margaret
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2017, 195 (07) : 912 - 920
  • [10] EFFECTS OF LUMACAFTOR/IVACAFTOR IN CYSTIC FIBROSIS PATIENTS HOMOZYGOUS FOR F508DEL CFTR MUTATION
    Melotti, P.
    Tridello, G.
    Pintani, E.
    Meneghelli, I
    Volpi, S.
    Spinelli, E.
    D'Orazio, C.
    PEDIATRIC PULMONOLOGY, 2018, 53 : 242 - 242
12345